TLDR:
- Applied DNA Sciences raised up to $58M through a private placement led by institutional DeFi and TradFi investors.
- The firm launched a yield-focused BNB treasury strategy holding more than $17M in BNB and BNB trust units.
- The company achieved $2.9M in annualized cost savings while shifting to a digital asset treasury model.
- Applied DNA’s BNB exposure includes 10,647 BNB tokens and an additional $5.3M direct purchase as of October 2025.
Applied DNA Sciences has made a bold move that’s turning heads in biotech and crypto.
The company closed a private placement deal worth up to $58 million, setting the stage for a new digital asset strategy. It’s steering toward yield-focused crypto holdings, starting with Binance’s BNB.
Investors from both traditional and decentralized finance joined the deal. According to a company press release, the plan could reshape how Applied DNA handles its balance sheet and liquidity.
The financing included $27 million in immediate proceeds and the potential for another $31 million if certain warrants are exercised.
The company said the funds came in a mix of cash, stablecoins, and BNB trust units. That trust alone gives it exposure to more than 10,600 BNB tokens, valued at about $11.7 million. It also disclosed another direct purchase of 4,900 BNB worth $5.3 million as of October 20, 2025.
BNB Holdings Strengthen Applied DNA’s Crypto Treasury Plan
Applied DNA described the move as a core part of its “BNB-focused digital asset treasury strategy.”
Chief Investment Officer Patrick Horsman said in the release that BNB represents a blockchain with growing institutional appeal. He added that the firm aims to generate yield from its holdings while maintaining exposure to high-quality crypto assets.
The newly raised capital will also help streamline operations. The company reported $2.9 million in annualized cost savings from internal adjustments made alongside the treasury shift.
CEO Clay Shorrock said Applied DNA is aligning resources around strategic priorities to ensure long-term stability and consistent value delivery.
The BNB allocation is designed to balance traditional cash management with on-chain yield opportunities. The company’s decision reflects a rising trend among public firms looking for blockchain-based treasury diversification.
Still, Applied DNA clarified that the new crypto exposure will depend on regulatory approvals for certain warrant exercises and the clean transfer of BNB trust units.
According to a tweet by Applied DNA Sciences (@BNBX_Corp), the company expects its combined BNB holdings to exceed $17 million once the full transaction settles. The plan places BNB at the center of its treasury framework and signals a deeper institutional embrace of crypto.
Crypto Meets Corporate Finance in Applied DNA’s New Strategy
Applied DNA’s transition comes as more firms explore hybrid treasury management between fiat and crypto.
By building a yield-focused BNB strategy, the company aims to optimize liquidity and generate returns from blockchain-based assets. The structure also reflects growing interest in digital asset treasuries among Nasdaq-listed entities.
The company emphasized that it will use the proceeds to implement its crypto strategy and maintain operational liquidity. The broader goal, according to its management, is sustainable growth through disciplined execution and diversification.
This blend of cost efficiency and on-chain exposure positions Applied DNA as one of the few biotech firms venturing into DeFi-driven treasury models. The move could offer investors a new way to gauge the intersection between blockchain assets and corporate finance.